(1-(5-Fluoropentyl)-3-(naphthalen-1-oyl)-6-nitroindole) | 335161-27-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (1-(5-Fluoropentyl)-3-(naphthalen-1-oyl)-6-nitroindole)
• 英文别名: [1-(5-fluoropentyl)-6-nitroindol-3-yl]-naphthalen-1-ylmethanone
• CAS: 335161-27-8
• 化学式: C24H21FN2O3
• 分子量: 404.4
• InChiKey: LNGVQORPSNNMSZ-UHFFFAOYSA-N

物化性质

• 沸点：
  612.9±45.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)
• 溶解度：
  二氯甲烷：20mg/mL； DMF：20mg/mL； DMSO：20mg/mL；乙醇：5mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  67.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• COMPOSITION AND METHODS TO IMPROVE STABILITY, DOSING, PHARMACODYNAMICS AND PRODUCT SHELF LIFE OF ENDOCANNABINOIDS, PHYTOCANNABINOIDS AND SYNTHETIC CANNABINOIDS DELIVERED BY NASAL INHALER
  申请人：Willinsky, Michael

  公开号：EP3247402A1

  公开（公告）日：2017-11-29
• COMPOSITIONS COMPRISING A CANNABINOID RECEPTOR BINDING LIGAND
  申请人：Novaliq GmbH

  公开号：EP3518921B1

  公开（公告）日：2021-08-11
• Methods and Compositions for Treating Mucosal Tissue Disorders
  申请人：The University of North Carolina at Chapel Hill

  公开号：US20150010654A1

  公开（公告）日：2015-01-08

  The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.
• [EN] TRANSDERMAL DELIVERY OF CANNABIDIOL<br/>[FR] ADMINISTRATION TRANSDERMIQUE DE CANNABIDIOL
  申请人：PIKE THERAPEUTICS INC 1219014 B C LTD

  公开号：WO2021074790A1

  公开（公告）日：2021-04-22

  Provided is a transdermal drug delivery system comprising cannabidiol, or its salt alone or in combinations thereof. Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and/or prevention of pain and/or inflammation.
• [EN] TRANSDERMAL AND/OR TOPICAL PHARMACEUTICAL FORMULATIONS COMPRISING CANNABIDIOL AND/OR TETRAHYDROCANNABINOL FOR THE TREATMENT OF CHRONIC PAIN<br/>[FR] FORMULATIONS PHARMACEUTIQUES TRANSDERMIQUES ET/OU TOPIQUES COMPRENANT DU CANNABIDIOL ET/OU DU TÉTRAHYDROCANNABINOL POUR LE TRAITEMENT DE LA DOULEUR CHRONIQUE
  申请人：PIKE THERAPEUTICS INC

  公开号：WO2021214545A1

  公开（公告）日：2021-10-28

  The current application relates to a transdermal or topical pharmaceutical formulation comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of chronical pain with reduced side effects in the patient. The transdermal or topical formulation can also be used for the treatment of various symptoms associated with multiple sclerosis (MS).